搜索
7220164Vol.7No.2Apr.2016NonferrousMetalsScienceandEngineering1674-9669201602-0117-07DOI10.13264/j.cnki.ysjskx.2016.02.021,、[1-2]，2-（2-Methylisoborneol2-MIB）[3-5].22-MIB1，2，3，3，1，3，1（1.，341000；2.，330001；3.，200092）：，Al3+2-（2-Methylisoborneol2-MIB）.Al3+3mg/L.，：，2mg/L，；，2-MIB.，.：；2-MIB；；：X703：AEffectoftwotypicalpre-oxidationprocessesonremovalofpreudanabaenasp.anditsmetabolites2-MIBduringcoagulationZHAOLaicai1,YUANBaoming2,MAXiaoxuan3，LILei3,CHENGuofang1，SHAOChen3，HELing1（1.SchoolofResourcesandEnveronmentEngineering,JiangxiUniversityofScienceandTechnology,Ganzhou341000,China;2.Propaganda＆EducationCenteroftheWorkSafetyofJiangxiProvince,Nanchang330001,China;3.CollegeofEnvironmentalScienceandEngineering,TongjiUniversity,Shanghai200092,China）Abstract:Withpreudanabaenasp.,thecommonalgaeinrawwater,asresearchobject,theremovalefficiencyofpreudanabaenasp.andthemetabolizedodorandtastecompound,2-MIBwasstudiedbyusingAl3+coagula-tion.TheresultsshowthattheoptimaldosageofAl3+is3mg/L.Meanwhile,pre-oxidationwithpotassiumper-manganateandsodiumhypochloritewereappliedinordertoenhancethecoagulation.Itisobservedthatlowconcentrationsofpotassiumpermanganatehasnosignificanteffectoncoagulationwhiletheperoxidationex-hibitsnegativeimpactonthecoagulationwhenMnO4-isincreasedto2mg/L,andthepre-oxidationwithsodi-umhypochloriteevenleadstothereleaseofintracellular2-MIB.Three-dimensionalfluorescencedataindi-catesthatpre-oxidationprocessleadsthereleaseofintracellularorganismsbycelllysis,whichwillhaveef-fectonthecoagulation.Keywords:preudanabaenasp.;2-MIB;pre-oxidationprocess;coagulation：2015-08-17：（51308398），（13DJ1400100）：（1984-），，，，，E-mail：lilei@tongji.edu.cn.，2-MIB，IOM[6-8].，：[9-11]、[12-16]、[17]、[18-19]、[20-21]、[22].2-MIB，.GC-MS2-MIB..11.11.1.1，.1.1.2，，Al2（SO4）3（Al2（SO4）3≥99.0%）.1.1.3AL204，X1R，SPX-250-G，GC/MS/MS//，F-4500，，，CX-31.1.2，2cm，2-MIB2-MIB.EEM，（25±1）℃，pH7.5±1，1000mL，10mL，，0.45μmPTFE，EEM.22.11，，3mg/L，61.48%.2-MIB，，，2-MIB，13.36%（2）.，2-MIB，[23].2.22.2.13，，30min，0.5mg/L、1mg/L2mg/L，6%、2%1%，，.60min，39%、36%34%，，2-MIB（1），2-MIB，0.5mg/L、1mg/L2mg/L，60min2-MIB0.07%、19.89%34.19%.（：，=）.1Fig.1Turbidityremovalundercoagulationwithdifferentinitialcoagulantdosage252015105035610121620NTU/（mg·L-1）2、2-MIBFig.2Changeoftotalandextracellular2-MIBaftercoagulationwithdifferentinitialcoagulantdosage35610121620/（mg·L-1）700060005000400030002000100002-MIB/（ng·L-1）2-MIB2-MIB2-MIB2-MIB20164118，：22-MIBC（KMnO4）/（mg·L-1）/min2-MIB/%2-MIB/（ng·L-1）0.51570.491335.723069.921316.526070.371200.841.01568.631399.083069.011239.846074.691438.682.01566.271387.683071.831284.246058.301610.282.2.22-MIB、2-MIB42.，.2-MIB2-MIB，，；，2-MIB（2），1.0mg/L2-MIB2.93.，，2-MIB.，2-MIB.2.3-，，EEM5.[24]，EOM，（I）（II）.IOM，（I）、（II）（III）..，，（EX500~580nm，EM540~620nm），.3Fig.3Turbidityremovalafterper-oxidationandcoagulationwithdifferentinitialKMnO4dosageexposure0.5mg/L1.0mg/L2.0mg/L806040200153060/%/min1、2-MIBTable1ChangeoftotalandExtracellular2-MIBafterper-oxidatioinandcoagulationwithdifferentinitialKMnO4dosageexposure：2-MIB5800ng/L,2-MIB1200ng/L.4Fig.4Turbidityremovalafterper-oxidationandcoagulationwithdifferentinitialNaClOdosageexposure：2-MIB5800ng/L,2-MIB1200ng/L.0.3mg/L0.6mg/L1.0mg/L403020100153060/%/min2、2-MIBTable2ChangeoftotalandExtracellular2-MIBafterper-oxidatioinandcoagulationwithdifferentinitialNaClOdosageexposure1011.152173.80300.162478.720.6347.232464.201025.433370.80309.133593.041.0343.052887.561049.082787.00302.284715.400.3340.751354.80C（KMnO4）/（mg·L-1）/min2-MIB/%2-MIB/（ng·L-1）721192.3.11.0mg/L，EOM360min，，.2.0mg/L，6，120min，，[25].150min，，（150~180min700600500400300300400500600700050100150200（a）EOMEM/nmEX/nm5EOM、IOMEEMFig.5EEMofEOMandIOM（b）IOM7006005004003003004005006007000100200300400EM/nmEX/nm62.0mg/LEEMFig.6EEMofextracellularPseudoanabaenasp.after2.0mg/Lpermanganatedosageexposure010152030580570560550540530520510500540550560570580590600610620EM/nmEX/nm（a）2.0mg/L0~120min010152030580570560550540530520510500540550560570580590600610620EM/nmEX/nm01020304050580570560550540530520510500540550560570580590600610620EM/nmEX/nm（b）2.0mg/L150min（c）2.0mg/L180min01020304050580570560550540530520510500540550560570580590600610620EM/nmEX/nmEM/nm01020304050580570560550540530520510500540550560570580590600610620EX/nm（d）2.0mg/L240min（f）2.0mg/L360min（e）2.0mg/L300min01020304050580570560550540530520510500540550560570580590600610620EM/nmEX/nm201641201304.0mV4848.6mV），，240min，（240~360min4560.6mV，4050.0mV3072.8mV），：（120min），0.059M·s（133.6min），，.，（240min），.75.0mg/L，2mg/L，，90min（9204.6mV），210min（210~360min946.1mV627.6mV）.2.3.20.5mg/L（8），10min（2122.4mV），（27279.9±5815.2mV）.，，，30min.，（1.0mg/L），（9），5min，9078.6mV.，，10min3760.0mV，3244.0mV.，，，，10min.，5min，.，.，.75.0mg/LEEMFig.7EEMofextracellularPseudoanabaenasp.after5.0mg/LpermanganatedosageexposureEM/nm01020304050580570560550540530520510500540550560570580590600610620EX/nmEM/nm580570560550540530520510500540550560570580590600610620EX/nm01020304050EM/nm580570560550540530520510500540550560570580590600610620EX/nm01020304050（f）5.0mg/L360min（e）5.0mg/L210min（d）5.0mg/L150minEM/nmEX/nm02040608058057056